Endovascular Engineering (E2) announced today that it raised $80 million in an oversubscribed Series C financing round.
Gilde Healthcare and Norwest co-led round to commercialize the Hēlo (R) Thrombectomy Platform ...
The funding round follows high-profile acquisitions by Boston Scientific and Stryker to pick up mechanical thrombectomy ...
MENLO PARK, Calif., Jan. 11, 2024 /PRNewswire/ -- Endovascular Engineering ("E2"), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that ...
MENLO PARK, Calif., Feb. 20, 2024 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous ...
The MarketWatch News Department was not involved in the creation of this content. MENLO PARK, Calif., March 19, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2") today announced that two ...
MENLO PARK, Calif., Feb. 18, 2025 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”) has secured $42 million in an oversubscribed Series B financing to advance its next generation clot removal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results